Proteomic characterization of the colorectal cancer response to chemoradiation and targeted therapies reveals potential therapeutic strategies
-
Published:2023-12
Issue:12
Volume:4
Page:101311
-
ISSN:2666-3791
-
Container-title:Cell Reports Medicine
-
language:en
-
Short-container-title:Cell Reports Medicine
Author:
Li Yan,
Wang Bing,
Ma Fahan,
Jiang Dongxian,
Wang Ying,
Li Kai,
Tan Subei,
Feng Jinwen,
Wang Yunzhi,
Qin Zhaoyu,
Xu Ganfei,
Tian Sha,
Zhang Xiaolei,
Xu Chen,
Wu Jiaxue,
Xu Jianmin,
Hou Yingyong,
Ding ChenORCID
Reference75 articles.
1. Colorectal cancer;Brenner;Lancet,2014
2. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer;André;N. Engl. J. Med.,2004
3. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome;Pucciarelli;Dis. Colon Rectum,2004
4. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS;Yoshino;Ann. Oncol.,2018
5. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer;Bokemeyer;Eur. J. Cancer,2015
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献